Assess Terlipressin for Hepatorenal Syndrome
Terlipressin (Terlivaz) will be the first FDA-approved med for hepatorenal syndrome with acute kidney injury (HRS-AKI).
HRS-AKI typically occurs in patients with cirrhosis and ascites who develop splanchnic vasodilation. This causes decreased perfusion to the kidneys.
The best treatment is a liver transplant...but many patients don’t qualify for or live long enough to get a transplant.